• Svenska

Oasmia logoOasmia logo

  • About Oasmia
    • Our Company
      Vision and targets
      Our technology
    • Production
      Research and development
    • Board of Directors
      Management
    • History
      Events
  • Market
    • Market Human Health
    • Market Animal Health
  • Governance
    • Governance Structure
      Corporate Governance Reports
      Articles of Association
    • General Meeting
      General Meetings
    • Board of Directors
      Board Committees
      Management
    • Auditor
      Code of Business Conduct and Ethics
  • Investors
    • Strategic investment for the future
      The Share
      Ownership Structure
    • Financial Reports
      Prospectus
      SEC Filings
      Info regarding delisting of ADS from NASDAQ US
    • Press Releases
      Calendar
    • Subscribe
      Contacts
  • Media
    • Press releases
    • Subscribe
    • Contacts
  • Career
    • Vacant positions
    • Contacts
  • Contacts
    • Offices
    • Investors
    • Media
    • Career
    • About Oasmia
      • Our Company
      • Vision and targets
      • Our technology
      • Production
      • Research and development
      • Board of Directors
      • Management
      • History
      • Events
    • Market
      • Market Human Health
      • Market Animal Health
    • Governance
      • Governance Structure
      • Corporate Governance Reports
      • Articles of Association
      • General Meeting
        • General Meetings
      • Board of Directors
        • Board Committees
      • Management
      • Auditor
      • Code of Business Conduct and Ethics
    • Investors
      • Strategic investment for the future
      • The Share
      • Ownership Structure
      • Financial Reports
      • Prospectus
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
      • Press releases
      • Calendar
      • Subscribe
      • Contacts
    • Media
      • Press releases
      • Subscribe
      • Contacts
    • Career
      • Vacant positions
      • Contacts
    • Contacts
      • Offices
      • Investors
      • Media
      • Career
    • Svenska
    March 19, 2019

    Extraordinary General Meeting 2019

    Extraordinary General Meeting was held on March 19, 2019 in Oasmias offices in Uppsala.

    The documentation from the Meeting is available in PDF format below.

    Documents

    • Minutes
      Swedish 19 March, 2019
    • Notice
      English 5 Febuary, 2019
    • Proxy
      English 2019
    oasmia2017-0567

    Improving the quality of life for humans and their animal companions

    At Oasmia Pharmaceutical AB we are developers of a new generation of drugs within the fields of human and veterinary oncology.

    Read more

    The Share

    September 18, 2019
    Oasmia Pharmaceutical
    6.03
    -1.23%
    Follow the share

    Share this page

    At Oasmia Pharmaceutical AB we are developers of a new generation of drugs within the fields of human and veterinary oncology. We aim to develop and manufacture novel anti-cancer formulations based on well-established cytostatics which, in comparison with the current alternatives, demonstrate improved properties, a reduced side-effect profile and an expanded therapeutic area. Our suite of oncology products in development is based on our proprietary research within nanotechnologies and company patents.

    Oasmia Pharmaceutical AB

    Vallongatan 1, 752 28 Uppsala, Sweden
    Tel +46 18 50 54 40
    Fax +46 18 51 08 73
    info@oasmia.com

    • Personal data
    • Cookies

    We uses cookies in order to optimize your use of our website. Read more about cookies.

    OK